Shares of Nano-X Imaging (NNOX.US), US medical imagining technology company, are slumping 25% today, erasing a big part of last week's gain. Shares of the company rallied last week after Nvidia disclosed that it holds a stake in the company worth around $380 thousand.
Nvidia is among investors' favorites after its shares rallied over 200% in 2023 on the back of AI-hype. It has been quite common over the past year for companies, who signed a partnership agreement with Nvidia, to see their share prices rally as investors expect those to benefit from AI revolution as well. It looks like a similar approach is being taken to companies in which Nvidia is holding a stake. However, in case of Nano-X Imaging it could be evidence that investors in such hot markets as we have today are acting first and thinking later.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appNvidia held a stake in Zebra Medical, an Israeli startup focused on using AI technology in reading medical images, since at least 2017, when it was first disclosed in regulatory filling. However, Zebra was acquired in 2021 by Nano-X Imaging in an all-stock merger, meaning that Nvidia received shares in Nano-X for its Zebra Medical shares.
Last week's disclosure from Nvidia was made via an 13F filling, which is a filling required by companies whose investment portfolio exceeds $100 million. Nvidia has likely surpassed this threshold last year, following IPO of Arm Holdings ($147 million Arm stake is the biggest in Nvidia's portfolio). Summing up, Nvidia most likely did not make any investment into Nano-X recently, and today's pullback on Nano-X stock like means that investors have realized it over the long US weekend.
Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
